Literature DB >> 24351509

Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scan.

Aritoshi Hattori1, Kenji Suzuki, Takeshi Matsunaga, Mariko Fukui, Yukio Tsushima, Kazuya Takamochi, Shiaki Oh.   

Abstract

OBJECTIVES: Adenocarcinoma in situ (AIS), which is considered to be pathologically non-invasive in the new International Association for the Study of Lung Cancer/the American Thoracic Society/the European Respiratory Society classification, might be present in patients who show a part-solid nodule on thin-section computed tomography (CT) scan.
METHODS: Between 2008 and 2011, 556 clinical Stage IA (c-Stage IA) lung cancer patients underwent pulmonary resection. For all the patients, the findings obtained by preoperative thin-section CT were reviewed and categorized as pure ground-glass nodule (GGN), part-solid nodule or pure-solid nodule based on the findings on thin-section CT, i.e. based on the consolidation/tumour ratio (CTR). A part-solid nodule was defined as a tumour with 0 < CTR < 1.0, which indicated focal nodular opacity that contained both solid and GGN components. All the patients were evaluated by positron emission tomography (PET), and the maximum standardized uptake value (SUVmax) was recorded. Several clinicopathological features were investigated to identify predictors of AIS in clinical Stage IA lung cancer patients with a part-solid nodule radiologically, using multivariate analyses.
RESULTS: One-hundred and twelve c-Stage IA lung cancer patients showed a part-solid appearance on thin-section CT. Among them, AIS was found in 10 (32%) of the tumours with 0 < CTR ≤ 0.5, in contrast to 3 (5%) with 0.5 < CTR < 1.0. According to multivariate analyses, SUVmax and CTR significantly predicted AIS in patients with a part-solid nodule (P = 0.04, 0.02). The mean SUVmax of the patients with AIS was 0.57 (0-1.6). Moreover, in the subgroup of part-solid nodule with a SUVmax of ≤1.0 and a CTR of ≤0.40, which were calculated as cut-off values for AIS based on the results for a receiver operating characteristic curve, 6 (40%) patients with these criteria showed a pathological non-invasive nature, even patients with a part-solid nodule.
CONCLUSIONS: Among c-Stage IA adenocarcinoma with a part-solid nodule on thin-section CT scan, an extremely low level of SUVmax could reflect a pure GGN equivalent radiologically and AIS pathologically. The preoperative tumour SUVmax on PET could yield important information for predicting non-invasiveness in patients with a part-solid nodule.

Entities:  

Keywords:  Adenocarcinoma in situ; Lung cancer; Part-solid nodule; Positron emission tomography

Mesh:

Substances:

Year:  2013        PMID: 24351509      PMCID: PMC3930213          DOI: 10.1093/icvts/ivt500

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  25 in total

Review 1.  Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment.

Authors:  Hiroyuki Sakurai; Yoh Dobashi; Eiki Mizutani; Hirochika Matsubara; Shoji Suzuki; Kunio Takano; Shunya Shindo; Masahiko Matsumoto
Journal:  Ann Thorac Surg       Date:  2004-11       Impact factor: 4.330

2.  The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.

Authors:  Yoshikazu Miyasaka; Kenji Suzuki; Kazuya Takamochi; Takeshi Matsunaga; Shiaki Oh
Journal:  Eur J Cardiothorac Surg       Date:  2012-12-11       Impact factor: 4.191

3.  Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease.

Authors:  O S Breathnach; D J Kwiatkowski; D M Finkelstein; J Godleski; D J Sugarbaker; B E Johnson; S Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  2001-01       Impact factor: 5.209

4.  Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography.

Authors:  Shun-ichi Watanabe; Toshio Watanabe; Kazunori Arai; Takahiko Kasai; Joji Haratake; Hiroshi Urayama
Journal:  Ann Thorac Surg       Date:  2002-04       Impact factor: 4.330

5.  Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning.

Authors:  K Kodama; M Higashiyama; H Yokouchi; K Takami; K Kuriyama; M Mano; T Nakayama
Journal:  Lung Cancer       Date:  2001-07       Impact factor: 5.705

6.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.

Authors:  M K Gould; C C Maclean; W G Kuschner; C E Rydzak; D K Owens
Journal:  JAMA       Date:  2001-02-21       Impact factor: 56.272

7.  Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung.

Authors:  K Suzuki; T Yokose; J Yoshida; M Nishimura; K Takahashi; K Nagai; Y Nishiwaki
Journal:  Ann Thorac Surg       Date:  2000-03       Impact factor: 4.330

Review 8.  Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.

Authors:  Johan Vansteenkiste; Barbara M Fischer; Christophe Dooms; Jann Mortensen
Journal:  Lancet Oncol       Date:  2004-09       Impact factor: 41.316

9.  "Early" peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan.

Authors:  Kenji Suzuki; Hisao Asamura; Masahiko Kusumoto; Haruhiko Kondo; Ryosuke Tsuchiya
Journal:  Ann Thorac Surg       Date:  2002-11       Impact factor: 4.330

10.  Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers.

Authors:  Y Shimosato; A Suzuki; T Hashimoto; Y Nishiwaki; T Kodama; T Yoneyama; T Kameya
Journal:  Am J Surg Pathol       Date:  1980-08       Impact factor: 6.394

View more
  8 in total

1.  The oncological outcomes of segmentectomy in clinical-T1b lung adenocarcinoma with a solid-dominant appearance on thin-section computed tomography.

Authors:  Aritoshi Hattori; Takeshi Matsunaga; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki
Journal:  Surg Today       Date:  2015-10-15       Impact factor: 2.549

Review 2.  Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS).

Authors:  Elizabeth R Tang; Andrew M Schreiner; Bradley B Pua
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

3.  Statistical analysis of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography ground-glass nodule findings.

Authors:  Kazuya Nishii; Akihiro Bessho; Nobuaki Fukamatsu; Yoshiko Ogata; Shinobu Hosokawa; Makoto Sakugawa; Mitsumasa Kaji
Journal:  Mol Clin Oncol       Date:  2018-07-16

4.  Solitary ground-glass opacity nodules of stage IA pulmonary adenocarcinoma: combination of 18F-FDG PET/CT and high-resolution computed tomography features to predict invasive adenocarcinoma.

Authors:  Jun Zhou; Yanli Li; Yiqiu Zhang; Guobing Liu; Hui Tan; Yan Hu; Jie Xiao; Hongcheng Shi
Journal:  Oncotarget       Date:  2017-04-04

5.  Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.

Authors:  Kazuya Takamochi; Kaoru Mogushi; Hideya Kawaji; Kota Imashimizu; Mariko Fukui; Shiaki Oh; Masayoshi Itoh; Yoshihide Hayashizaki; Weijey Ko; Masao Akeboshi; Kenji Suzuki
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

Review 6.  [Advance in Diagnose and Treatment Strategies of Adenocarcinoma in Situ].

Authors:  Yangbo Qiu; Yang Shen-Tu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-09-20

7.  Folate receptor-positive circulating tumor cells in the preoperative diagnosis of indeterminate pulmonary nodules.

Authors:  Zhixin Li; Jianqiao Cai; Yongqiang Zhao; Jie Cai; Xiaogang Zhao
Journal:  J Clin Lab Anal       Date:  2022-08-10       Impact factor: 3.124

8.  Comparison of different automated lesion delineation methods for metabolic tumor volume of 18F-FDG PET/CT in patients with stage I lung adenocarcinoma.

Authors:  Xiao-Yi Wang; Yan-Feng Zhao; Ying Liu; Yi-Kun Yang; Zheng Zhu; Ning Wu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.